0001104659-23-072396.txt : 20230616
0001104659-23-072396.hdr.sgml : 20230616
20230616184004
ACCESSION NUMBER: 0001104659-23-072396
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230616
DATE AS OF CHANGE: 20230616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mehta Vimal
CENTRAL INDEX KEY: 0001733369
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38410
FILM NUMBER: 231022768
MAIL ADDRESS:
STREET 1: 780 EAST MAIN STREET
STREET 2: C/O BIOXCEL THERAPEUTICS, INC.
CITY: BRANFORD
STATE: CT
ZIP: 06405
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioXcel Therapeutics, Inc.
CENTRAL INDEX KEY: 0001720893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821386754
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-643-8060
MAIL ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
tm2319006-2_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-06-14
0
0001720893
BioXcel Therapeutics, Inc.
BTAI
0001733369
Mehta Vimal
C/O BIOXCEL THERAPEUTICS, INC.
555 LONG WHARF DRIVE, 12TH FLOOR
NEW HAVEN
CT
06511
1
1
0
0
CEO and President
1
Common Stock
2023-06-14
4
M
0
2609
A
39903
D
Common Stock
2023-06-15
4
M
0
30000
0.41
A
69903
D
Common Stock
2023-06-15
4
S
0
21988
21.41
D
47915
D
Common Stock
2023-06-15
4
S
0
8012
21.90
D
39903
D
Common Stock
2023-06-16
4
M
0
30000
0.41
A
69903
D
Common Stock
2023-06-16
4
S
0
24987
20.01
D
44916
D
Common Stock
2023-06-16
4
S
0
4266
20.90
D
40650
D
Common Stock
2023-06-16
4
S
0
747
21.89
D
39903
D
Common Stock
2000
I
By spouse
Restricted Stock Units
2023-06-14
4
M
0
2609
0
D
Common Stock
2609
28704
D
Stock Option (Right to Buy)
0.41
2023-06-15
4
M
0
30000
0
D
2027-08-23
Common Stock
30000
324000
D
Stock Option (Right to Buy)
0.41
2023-06-16
4
M
0
30000
0
D
2027-08-23
Common Stock
30000
294000
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.83 to $21.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.83 to $22.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.57 to $20.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.59 to $21.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
The option is fully vested and exercisable.
/s/ Richard Steinhart, as Attorney in Fact for Vimal Mehta, Ph.D.
2023-06-16